Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibition of HDAC attenuates VEGF signalling, which is important for vascular morphogenesis and endothelial differentiation [195].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [195]
Citations
Cites
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483 · cited 7×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 4×
“HDAC have been associated with a repression of transcription (Struhl, 1998) and their inhibition should relieve gene silencing.”
BackgroundInfluentialAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“Antiangiogenic therapy of cancers o ers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability, homogeneity and low mutational rate of endothelial cells (Boehm et al., 1997).”
BackgroundA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · cited 2×
“By using speci®c inhibitors, mainly TSA and SAHA (Yoshida et al., 1990; Richon et al., 1998) in di erent models based on in vitro, ex vivo and in vivo assays, we demonstrated that HDAC inhibition suppresses the spontaneous or VEGFinduced angiogenesis.”
BackgroundMethodSelf-citationHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731 · cited 7×
“At the time that we were preparing this manuscript, a study reporting the involvement of histone deacetylases in angiogenesis was published by Kim et al. (2001).”
BackgroundMethodInfluentialKijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps
Vittet, D., Prandini, M., Berthier, R., Schweitzer, A., Martin-Sisteron, H., Uzan, G., & Dejana, E. (1996) · Blood · doi:10.1182/blood.v88.9.3424.bloodjournal8893424 · Cited by 472 · cited 1×
“Capillary-like structures formation was analysed by the expression of CD31 in whole mount immuno¯uorescence as reported by Vittet et al. (1996).”
MethodNeuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.1.233 · Cited by 458 · cited 5×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialDeroanne, C. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00233-9 · Cited by 256 · cited 1×
“Culture medium, Oncogene HUVEC were induced to organize into a network of tube-like structures as described (Deroanne et al., 1996, 2001).”
MethodSelf-citation
Cited by
Items 101–200 of 406
Angiostatic activity of DNA methyltransferase inhibitors
Hellebrekers, D. M. E. I., Jair, K.-W., Viré, E. A., Eguchi, S., Hoebers, N., Fraga, M. F., Esteller, M., Fuks, F., Baylin, S. B., van Engeland, M., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0417 · Cited by 99
“Because inhibitory effects of HDAC inhibitors on endothelial cell growth have been described previously (16, 17), the HDAC inhibitor TSA was included as a positive control.”
BackgroundRamaswamy, B., Fiskus, W., Cohen, B., Pellegrino, C., Hershman, D. L., Chuang, E., Luu, T., Somlo, G., Goetz, M., Swaby, R., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1928-x · Cited by 88
“Finally, HDACi also alter vascular endothelial growth factor (VEGF) signaling, exhibit antiangiogenic activity, and enhance the activity of other VEGF-directed antiangiogenic agents [13].”
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
Yang, F., Lee, G., & Fan, Y. (2024) · Angiogenesis · doi:10.1007/s10456-024-09913-z · Cited by 94
“…targeting HDACs, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), hold promise in anti-angiogenesis therapy, as they modulate the transcription of several crucial pro-angiogenic signaling components, including receptors VEGFR1 and VEGFR2 [84], HIF-1α, and VEGF [85].”
BackgroundTherapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
Miller, C. P., Singh, M. M., Rivera-Del Valle, N., Manton, C. A., & Chandra, J. (2011) · BioMed Research International · doi:10.1155/2011/514261 · Cited by 86
“These antiangiogenic effects have been observed in different cancer models both in vitro and in vivo [34–36].”
BackgroundHDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 95
Mineur, P., Colige, A., Deroanne, C., Dubail, J., Kesteloot, F., Habraken, Y., Noël, A., Vöö, S. A., Waltenberger, J. L., Lapiere, C. M., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703052 · Cited by 100
Self-citationThe role of different VEGF isoforms in scar formation after glaucoma filtration surgery
Bergen, T. V., Vandewalle, E., de Veire, S. V., Dewerchin, M. A., Stassen, J., Moons, L., & Stalmans, I. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.08.016 · Cited by 93
“Additionally, HUVEC (Castro-Rivera et al., 2004; Deroanne et al., 2002; Kokolakis et al., 2006; Soker et al., 1998; Tirand et al., 2006) and certain types of fibroblasts (Haag et al.”
BackgroundThe Role of Angiogenesis in Human Non-Hodgkin Lymphomas
Ribatti, D., Nico, B., Ranieri, G., Specchia, G., & Vacca, A. (2013) · Neoplasia · doi:10.1593/neo.121962 · Cited by 95
“Successful therapy with vorinostat was associated with a reduced MVD and an increase of the antiangiogenic molecule thrombospondin-1 following treatment [111].”
BackgroundThe Hypoxia-Inducible Factor and Tumor Progression Along the Angiogenic Pathway
Brahimi-Horn, M. C., & Pouysségur, J. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)42004-x · Cited by 100
Histone modification enzymes: novel targets for cancer drugs
Kristeleit, R. S., Stimson, L., Workman, P., & Aherne, W. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.135 · Cited by 95
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 89
“TSA also inhibited the sprouting of capillaries from ex vivo rat aortic rings and VEGF-induced expression of VEGFR1, VEGFR2 and neuropilin-1 [108].”
BackgroundInfluentialMolecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity
Maulucci, N., Chini, M. G., Micco, S. D., Izzo, I., Cafaro, E., Russo, A., Gallinari, P., Paolini, C., Nardi, M. C., Casapullo, A., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0686256 · Cited by 89
Dubail, J., Kesteloot, F., Deroanne, C., Motté, P., Lambert, V., Rakic, J., Lapière, C., Nusgens, B., & Colige, A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0431-6 · Cited by 94
“1 mM b-mercaptoethanol, and 10 ng/ml of VEGF to induce cell clustering and differentiation into endothelial cells [30].”
Self-citationThe Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
Cosenza, M., & Pozzi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082337 · Cited by 88
“Indeed, the HDACs inhibitors are able to increase the acetylation of the pro-angiogenic factor HIF-1α determining its degradation and reducing the expression of the factor VEGF and angiopoietin [110].”
BackgroundGrabiec, A. M., Tak, P. P., & Reedquist, K. A. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2489 · Cited by 90
“Class III silent information regulator 2 (sirtuin) HDACs (Sirt1 to Sirt7) are nicotinamide adenosine dinucleotide-dependent enzymes, structurally unrelated to class I, class II and class IV HDACs.”
BackgroundInfluentialPhase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
Drappatz, J., Lee, E. Q., Hammond, S., Grimm, S. A., Norden, A. D., Beroukhim, R., Gerard, M., Schiff, D., S., A., Batchelor, T. T., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0717-z · Cited by 84
Zhang, C., Yang, C., Feldman, M. J., Wang, H., Pang, Y., Maggio, D. M., Zhu, D., Nesvick, C. L., Dmitriev, P., Bullova, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18125 · Cited by 80
“However, it is the other classes of HDACs held largely accountable for angiogenesis initiation and propagation largely through the modification of nonhistone proteins [32-40].”
BackgroundAspriţoiu, V. M., Stoica, I., Bleoţu, C., & Diaconu, C. C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689962 · Cited by 90
Inhibition of histone deacetylase as a new mechanism of teratogenesis
Menegola, E., Renzo, F. D., Broccia, M. L., & Giavini, E. (2006) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20082 · Cited by 88
The emerging role of lysine acetylation of non-nuclear proteins
Close, P., Creppe, C., Gillard, M., Ladang, A., Chapelle, J.-P., Nguyen, L., & Chariot, A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0252-7 · Cited by 89
Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials
Kim, S. H., Ahn, S.-H., Han, J., Lee, H. W., Lee, H. Y., Lee, Y., Kim, M. R., Kim, K. W., Kim, W. B., & Hong, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.149 · Cited by 83
“Another HDAC inhibitor, TSA, also blocked angiogenesis in vitro and in vivo by altering the expression of angiogenesis-related factors such as vascular endothelial growth factor (VEGF) and VEGF signaling [28,29].”
BackgroundManiar, K., Moideen, A., Mittal, A., Patil, A., Chakrabarti, A., & Banerjee, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.003 · Cited by 77
“Butyrate may also have a role in the secondary cancer prevention, by inhibiting angiogenesis via inhibition of formation of pro-angiogenic factors such as VEGF-1[289] and HIF[290].”
BackgroundLiu, T., Castelo‐Branco, P., Rabkin, S. D., & Martuza, R. L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.58 · Cited by 76
“Interestingly, in addition to their antitumoral effect, certain HDACIs have been shown to exert antiangiogenic activities [9,22, 23], and both characters are shared by oncolytic HSVs [24].”
BackgroundHenno, A., Blacher, S., Lambert, C., Colige, A., Seidel, L., Noël, A., Lapiere, C. M., de la Brassinne, M., & Nusgens, B. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08889.x · Cited by 82
Self-citationWhetstine, J. R., Cerón, J., Ladd, B., Dufourcq, P., Reinke, V., & Shi, Y. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.006 · Cited by 81
Kurschat, P., Bielenberg, D. R., Rossignol, M., Stahl, A., & Klagsbrun, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507860200 · Cited by 76
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Patel, M. D., Vogelbaum, M. A., Barnett, G. H., Jalali, R., & Ahluwalia, M. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703177 · Cited by 81
“Histone hyperacetylation can also degrade HIF-1a and decrease VEGF expression leading to anti-angiogenetic sequelae [131].”
BackgroundAdhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
New anti-cancer strategies: Epigenetic therapies and biomarkers
Balch, C. (2005) · Frontiers in bioscience · doi:10.2741/1668 · Cited by 78
Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention
Eccles, S. A. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041820se · Cited by 89
Tsou, P., Wren, J. D., Amin, M. A., Schiopu, E., Fox, D. A., Khanna, D., & Sawalha, A. H. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39828 · Cited by 73
“VEGF and hypoxia-inducible factor (24,25), affect class”
Targeting triple negative breast cancer with histone deacetylase inhibitors
Fedele, P., Orlando, L., & Cinieri, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1386172 · Cited by 75
“Furthermore, it has been shown that HDACis have an anti angiogenic effect, decrease the expression of vascular endothelial growth factor receptor [27], and inhibit proliferation, invasion, migration, and adhesion of endothelial cells [67].”
BackgroundPhase II trial of vorinostat in advanced melanoma
Haas, N. B., Quirt, I. C., Hotte, S. J., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0066-9 · Cited by 72
“Based on these observations and a potential anti-angiogenic role of vorinostat [23–25], we hypothesized that (1) patients with elevated serum bFGF levels would have more aggressive melanoma, which might respond to vorinostat; and (2) levels of serum VEGF and bFGF would decrease in response to vorinostat therapy.”
BackgroundBrazelle, W., Kreahling, J. M., Gemmer, J., Ma, Y., Cress, W. D., Haura, E., & Altiok, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014335 · Cited by 70
“Besides direct anti-tumorigenic effects, suppression of angiogenesis by HDACis might also have an impact on tumor growth inhibition [4].”
BackgroundWaltregny, D., North, B. J., Mellaert, F. V., de Leval, J., Verdin, E. M., & CASTRONOVO, V. (2004) · PubMed · doi:10.4081/897 · Cited by 77
Self-citationSegersten, U., Holm, P. K., Björklund, P., Hessman, O., Nordgren, H., Binderup, L., Åkerström, G., Hellman, P., & Westin, G. (2005) · Breast Cancer Research · doi:10.1186/bcr1332 · Cited by 72
“28S rRNA was used as internal standard [30].”
MethodJeon, H. S., Lee, S. Y., Lee, E. J., Yun, S. C., Cha, E. J., Choi, E. J., Na, M. J., Park, J. Y., Kang, J., & Son, J. W. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.012 · Cited by 76
Andersen, C. L., McMullin, M. F., Ejerblad, E., Zweegman, S., Harrison, C. N., Fernandes, S., Bareford, D., Knapper, S., Samuelsson, J., Löfvenberg, E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12416 · Cited by 72
“…and/or apoptotic cell death (Butler et al, 2002; Deroanne et al, 2002; Catley et al, 2003; de Ruijter et al, 2003; Atadja et al, 2004; Bradbury et al, 2005) and also to inhibit endothelial cell proliferation and angiogenesis in vivo (Deroanne et al, 2002; Rossig et al, 2002; Qian et al, 2004).”
BackgroundButyrate modulates gene and protein expression in human intestinal endothelial cells
Ogawa, H., Rafiee, P., Fisher, P. J., Johnson, N. A., Otterson, M. F., & Binion, D. G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.026 · Cited by 70
Berendsen, S., Broekman, M. L. D., Seute, T., Snijders, T. J., van Es, C. A., Vos, F. D., Regli, L., & Robe, P. A. J. T. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.694425 · Cited by 74
“Like other HDAC inhibitors, VPA was shown to decrease the expression of VEGF, a potent inducer of angiogenesis, in several cancer cell types among which are prostate and colon carcinomas [119-121] and malignant gliomas [122].”
BackgroundStiborová, M., Eckschlager, T., Poljaková, J., Hraběta, J., Adam, V., Kizek, R., & Frei, E. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802884286 · Cited by 78
“[75].”
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.204 · Cited by 75
Roh, M.-S., Kim, C. W., Park, B. S., Kim, G. C., Jeong, J. H., Kwon, H., Suh, D. J., Cho, K. H., Yee, S.-B., & Yoo, Y. H. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000038037.68908.6e · Cited by 72
Epigenetic modification regulates tumor progression and metastasis through EMT (Review)
Tan, T., Shi, P., Abbas, M. N., Wang, Y., Xu, J., Chen, Y., & Cui, H. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5360 · Cited by 72
Ellis, L., & Пили, Р. (2010) · Pharmaceuticals · doi:10.3390/ph3082441 · Cited by 71
“Semaphoring III Endothelial Inhibits Up-regulation [65]”
Second-line treatment for malignant pleural mesothelioma
Ceresoli, G. L., Zucali, P. A., Gianoncelli, L., Lorenzi, E., & Santoro, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.09.003 · Cited by 70
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Marchion, D. C., Bicaku, E., Turner, J. G., Schmitt, M. L., Morelli, D. R., & Munster, P. N. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0985 · Cited by 60
Unraveling the epigenetic code of cancer for therapy
Smith, L. T., Otterson, G. A., & Plass, C. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.07.005 · Cited by 71
Selective class IIa HDAC inhibitors: myth or reality
Giorgio, E. D., Gagliostro, E., & Brancolini, C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1727-8 · Cited by 68
Jazirehi, A. R. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833dad91 · Cited by 67
The Epigenetic Regulation of Wound Healing
Lewis, C. J., Mardaryev, A. N., Sharov, A. A., Fessing, M. Y., & Botchkarev, V. A. (2014) · Advances in Wound Care · doi:10.1089/wound.2014.0522 · Cited by 68
“VEGF signaling, which is critical for vascular morphogenesis and endothelial differentiation, is attenuated by HDAC inhibition.76 Additionally, human umbilical vein endothelial cells fail to form capillary buds following treatment with TSA and SAHA.76 The PcG family of proteins are also involved in the processes of an…”
BackgroundTargeted therapies for advanced non-small-cell lung cancer: Current status and future implications
Custodio, A., Méndez, M., & Provencio, M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.001 · Cited by 66
Epigenetics in the Vascular Endothelium: Looking From a Different Perspective in the Epigenomics Era
Yan, M. S., & Marsden, P. A. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305043 · Cited by 69
Papeleu, P., Vanhaecke, T., Elaut, G., Vinken, M., Henkens, T., Snykers, S., & Rogiers, V. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935639 · Cited by 64
Molecular Mechanisms of Hepatoblastoma
Zhang, Y., Solinas, A., Cairo, S., Evert, M., Chen, X., & Calvisi, D. F. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1722645 · Cited by 65
Henno, A., Blacher, S., Lambert, C. A., Deroanne, C., Noël, A., Lapiere, C. M., Brassinne, M. D. L., Nusgens, B., & Colige, A. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.12.006 · Cited by 60
“For VEGF-A and PlGF, forward and reverse primers were chosen in regions surrounding the alternatively skipped sequences, allowing the discrimination of the various splice variants on the basis of the size of their amplification product [29].”
BackgroundSelf-citationDeacetylase inhibitors - focus on non-histone targets and effects
Ocker, M. (2010) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v1.i5.55 · Cited by 67
On the epigenetics of vascular regulation and disease
Schleithoff, C., Voelter‐Mahlknecht, S., Dahmke, I. N., & Mahlknecht, U. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-7 · Cited by 63
“The eNOS mRNA level not only depends on the transcriptional activity at the promoter level, [111]. the post-transcriptional modulation of the eNOS mRNA half-life is probably the determining factor that influences the actual amount of eNOS mRNA. eNOS mRNA can be stabilized through exposure of endothelial cells to 3-hyd…”
BackgroundInfluentialMühlethaler‐Mottet, A., Meier, R., Flahaut, M., Bourloud, K. B., Nardou, K., Joseph, J., & Groß, N. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-55 · Cited by 60
“In addition to the role of HDACi in reducing tumour initiation by their effects on cell proliferation and survival, HDACi were found to repress angiogenesis in vitro and in vivo, and to reduce the expression of pro-angiogenic factors, such as HIF and VEGF [5,8,9].”
BackgroundPhase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Peters, K. B., Lipp, E., Miller, E., Herndon, J. E., McSherry, F., Desjardins, A., Reardon, D. A., & Friedman, H. S. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2724-1 · Cited by 59
“Specifically, in vitro studies revealed that VOR can upregulate semaphorin III, a VEGF competitor, expression, and other histone deacetylase inhibitors can suppress the expression of VEGR receptors [33].”
BackgroundDeleu, S., Lemaire, M., Arts, J., Menu, E., Valckenborgh, E. V., King, P., Broek, I. V., Raeve, H. D., Camp, B. V., Croucher, P. I., et al. (2009) · Leukemia · doi:10.1038/leu.2009.121 · Cited by 63
Richardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Hájek, R., Špıčka, I., Dimopoulos, M. A., Moreau, P., Siegel, D. S. D., Jagannath, S., & Anderson, K. C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.006 · Cited by 58
“Histone deacetylase inhibitors (including vorinostat and romidepsin) have been shown to suppress the expression of VEGF and VEGF-induced angiogenesis in concert with downregulation of hypoxia-inducible factor-1 alpha (HIF1- ) expression and activity [25,29,52].”
BackgroundCholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug
Brioschi, A., Zara, G. P., Calderoni, S., Gasco, M. R., & Mauro, A. (2008) · Molecules · doi:10.3390/molecules13020230 · Cited by 61
Butyrate Properties in Immune-Related Diseases: Friend or Foe?
Anshory, M., Effendi, R. M. R. A., Kalim, H., Dwiyana, R. F., Suwarsa, O., Nijsten, T. E. C., Nouwen, J. L., & Thio, H. B. (2023) · Fermentation · doi:10.3390/fermentation9030205 · Cited by 62
Wheler, J. J., Jankú, F., Falchook, G. S., Jackson, T. L., Fu, S., Naing, A., Tsimberidou, A. M., Moulder, S., Hong, D. S., Yang, H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2384-1 · Cited by 56
“Histone deacetylase inhibitors have also been shown to downregulate angiogenesis-related gene expression in endothelial and tumor cells [11, 12].”
Inhibition of histone deacetylase causes emphysema
Mizuno, S., Yasuo, M., Bogaard, H. J., Kraskauskas, D., Natarajan, R., & Voelkel, N. F. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00207.2010 · Cited by 60
“Indeed, we reproduced the antiangiogenic actions of TSA, which have been documented in cancer cell lines and in in vitro experiments, which demonstrated that TSA inhibits VEGF-stimulated angiogenesis of human umbilical vein endothelial cells (14, 41).”
BackgroundThe potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
Gridelli, C., Rossi, A., & Maione, P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.002 · Cited by 54
An (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000204 · Cited by 58
Wu, S., Luo, Z., Yu, P.-J., Xie, H., & He, Y.-W. (2016) · Biological Chemistry · doi:10.1515/hsz-2015-0215 · Cited by 51
“Therefore 1 μM SAHA was used for further study to investigate the effects of SAHA on the in vitro motility of TNBC cells according to our results and published literatures (Deroanne et al., 2002; Lugrin et al., 2009).”
ResultHistone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091883 · Cited by 51
“SAHA, including several other HDACi, have been reported to have anti-angiogenic properties by decreasing the expression of several pro-angiogenic factors, including vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1a (HIF1a) which is independent of p53 [140,169].”
BackgroundSystemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 65
Proanthocyanidins, from Ribes nigrum leaves, reduce endothelial adhesion molecules ICAM-1 and VCAM-1
Garbacki, N., Kinet, M., Nusgens, B., Desmecht, D. J.-M., & Damas, J. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-9 · Cited by 53
“primers (Table 1), 10 ng of total RNA and, when available, a known copy number of an original synthetic internal standard of RNA, in 25 μl reaction mixture [20].”
BackgroundSelf-citationAkasaka, K., Maesawa, C., Shibazaki, M., Maeda, F., Takahashi, K., Akasaka, T., & Masuda, T. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.406 · Cited by 60
“HDAC1 overexpression represses tumor suppressor genes, such as p53 and the von Hippel-Lindau gene, associated with angiogenesis (Kim et al., 2001; Deroanne et al., 2002).”
BackgroundHistone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
Chen, X., He, Y., Fu, W., Sahebkar, A., Tan, Y., Xu, S., & Li, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.581015 · Cited by 55
HDACi - going through the mechanisms
Wańczyk, M., Roszczenko, K., Marcinkiewicz, K., Bojarczuk, K., Kowara, M., & Winiarska, M. (2010) · Frontiers in bioscience · doi:10.2741/3691 · Cited by 56
“Both TsA and vorinostat have a potential to prevent human umbilical cord endothelial cells (HUVEC) stimulated by VEGF from invading a type I collagen gel and forming tubular structures (133).”
BackgroundHistone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Budillon, A., Gennaro, E. D., Bruzzese, F., Rocco, M., Manzo, G., & Caraglia, M. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207780832450 · Cited by 57
A novel imaging‐based high‐throughput screening approach to anti‐angiogenic drug discovery
Evensen, L., Micklem, D., Link, W., & Lorens, J. B. (2009) · Cytometry Part A · doi:10.1002/cyto.a.20808 · Cited by 50
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
Mrakovcic, M., Bohner, L. O. L., Hanisch, M. R., & Fröhlich, L. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123952 · Cited by 52
“Moreover, HDACi disable tumor angiogenesis by attenuation of vascular endothelial growth factor receptor (VEGFR) expression [138].”
BackgroundStevenson, A. W., Deng, Z., Allahham, A., Prêle, C. M., Wood, F. M., & Fear, M. W. (2021) · Experimental Dermatology · doi:10.1111/exd.14414 · Cited by 50
Höti, N., Chowdhury, W. H., Hsieh, J., Sachs, M. D., Lupold, S. E., & Rodríguez, R. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.009 · Cited by 49
Chung, Y., Troy, H., Kristeleit, R. S., Aherne, W., Jackson, L. E., Atadja, P. W., Griffiths, J. R., Judson, I. R., Workman, P., Leach, M. O., et al. (2008) · Neoplasia · doi:10.1593/neo.07834 · Cited by 48
Tran, K. M., Risingsong, R., Royce, D. B., Williams, C. R., Sporn, M. B., Pioli, P. A., Gediya, L. K., Njar, V. C. O., & Liby, K. T. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs319 · Cited by 50
“In addition to its anti-tumor effects, SAHA exhibits anti-inflammatory and anti-angiogenic properties [22,23].”
BackgroundBiological Activities in Animal Models.
Mori, H., Abe, F., Furukawa, S., Furukawa, S., Sakai, F., Hino, M., & Fujii, T. (2003) · The Journal of Antibiotics · doi:10.7164/antibiotics.56.80 · Cited by 47
Fakih, M., Groman, A. E., McMahon, J., Wilding, G. E., & Muindi, J. R. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1762-1 · Cited by 47
Kakihana, M., Ohira, T., Chan, D. C. F., Webster, R. B., Kato, H., Drabkin, H. A., & Gemmill, R. M. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181bc9419 · Cited by 46
Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
Martínez, V. G., Munera-Maravilla, E., Bernardini, A., Rubio, C., Suárez-Cabrera, C., Segovia, C., Lodewijk, I., Dueñas, M., Martínez‐Fernández, M., & Paramio, J. M. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01125 · Cited by 48
Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
Chinnaiyan, P., Varambally, S., Tomlins, S. A., Ray, S. S., Huang, S., Chinnaiyan, A. M., & Harari, P. M. (2005) · International Journal of Cancer · doi:10.1002/ijc.21465 · Cited by 47
“Recent studies have demonstrated the effect of HDAC inhibition on tumor angiogenesis by down-modulation of vascular endothelial growth factor (VEGF) and HIF1-a.44,45 The VEGF molecule is critical for tumor angiogenesis, is highly expressed in prostate cancer cells and has been shown to positively correlate with stage,…”
BackgroundPhase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
Strickler, J. H., Starodub, A., Jia, J., Meadows, K. L., Nixon, A. B., Dellinger, A. E., Morse, M. A., Uronis, H. E., Marcom, P. K., Zafar, S. Y., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1911-1 · Cited by 46
“In addition, panobinostat has been shown to directly inhibit expression of pro-angiogenic proteins VEGFR1, VEGFR2, and neuropilin-1 [14].”
Grassadonia, A., Cioffi, P., Simiele, F., Iezzi, L., Zilli, M., & Natoli, C. (2013) · Cancers · doi:10.3390/cancers5030919 · Cited by 48
“Another well described anticancer effect of HDACIs is the inhibition of angiogenesis, resulting from the downregulation of genes involved in angiogenesis, such as the vascular endothelial growth factor (VEGF) and the endothelial nitric oxide synthase (eNOS) [32–34].”
BackgroundHistone Deacetylase Inhibitors and Rational Combination Therapies
Grant, S., & Dai, Y. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00006-9 · Cited by 50
Hrgović, I., Doll, M., Kleemann, J., Wang, X., Zöller, N. N., Pinter, A., Kippenberger, S., Kaufmann, R., & Meißner, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2807-y · Cited by 44
“In addition, it has been reported that various HDACi impaired angiogenesis in vitro and in vivo [27–30].”
BackgroundHsieh, Y., Su, I., Yen, C.-J., Tsai, T., Tsai, H.-W., Tsai, H.-N., Huang, Y., Chen, Y., Ai, Y.-L., Kao, L.-Y., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs365 · Cited by 43
Peulen, O., Gonzalez, A., Peixoto, P., Turtoï, A., Mottet, D., Delvenne, P., & Castronovo, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075102 · Cited by 44
Self-citationHakami, N., Dusting, G. J., & Peshavariya, H. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12885 · Cited by 47
Sahin, M. A., Şahın, E., Gümüşlü, S., Erdoğan, A., & Gültekin, M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9253-0 · Cited by 47
Differential molecular mechanistic behavior of HDACs in cancer progression
Singh, T., Kaur, P., Singh, P., Singh, S., & Munshi, A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01770-4 · Cited by 46
“TSA is a reversible HDAC inhibitor that targets HDAC7 and HDAC8, preventing the removal of acetyl ions from histone proteins [208].”
BackgroundInfluentialEpigenetic regulation of key vascular genes and growth factors
Turunen, M. P., & Yla-Herttuala, S. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr109 · Cited by 41
“HDAC inhibitors have been shown to inhibit VEGF signalling.(43) Authors showed that TSA and SAHA prevented HUVEC from invading a type-I collagen gel and”
BackgroundCardiotoxicity of Molecularly Targeted Agents
Hedhli, N., & Russell, K. S. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960636 · Cited by 43
“In addition, HDAC inhibitors can inhibit angiogenesis by increasing acetylation of the proangiogenic factor HIF-1 alpha and enhancing its degradation [118] and decreasing the expression of VEGF receptor [119].”
BackgroundBidulescu, A., & Bacanamwo, M. (2011) · Wiley eBooks · doi:10.1002/9780470959824.ch10 · Cited by 41
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 43
Metadata
- Authors
- Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., & Castronovo, V.
- Affiliations
- University of Liège (BE)
- University of California, San Francisco (US)
- Corresponding author
- Deroanne, Christophe F
- Venue
- Oncogene
- Published
- 2002-01-17
- Volume
- 21
- Issue
- 3
- Pages
- 427-436
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2031671750
- Cited by
- 400
- References
- 25
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 24 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 20 · 2013: 15 · 2012: 27
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- histone deacetylase inhibitors, trichostatin A, vorinostat, angiogenesis inhibitors, VEGF signaling, VEGF receptors, VEGFR1, VEGFR2, neuropilin-1, human umbilical vein endothelial cells, capillary formation, angiogenesis, chromatin remodeling
- MeSH terms
- Vorinostat, Animals, Aorta, Carrier Proteins, Cells, Cultured, Chick Embryo, Chorion, Endothelium, Vascular, Histone Deacetylases, Humans, Hydroxamic Acids, Lymphokines, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Nerve Tissue Proteins, RNA, Messenger, RNA, Ribosomal, 28S, Umbilical Veins, Blotting, Western, Signal Transduction, Up-Regulation, Endothelial Growth Factors, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Semaphorin-3A, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.